Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -34,352 | -17,506 | -71,176 | -47,120 | -34,644 |
| Depreciation Amortization | 2,361 | 1,108 | 3,690 | 2,859 | 1,969 |
| Accounts payable and accrued liabilities | 1,873 | 2,421 | 1,907 | 4,572 | 3,205 |
| Other Working Capital | -6,405 | -2,998 | -5,956 | -1,224 | -8,115 |
| Other Operating Activity | 1,261 | -878 | 12,000 | 720 | 542 |
| Operating Cash Flow | $-35,262 | $-17,853 | $-59,535 | $-40,193 | $-37,043 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -991 | -454 | -7,512 | -5,497 | -3,598 |
| Investing Cash Flow | $-991 | $-454 | $-7,512 | $-5,497 | $-3,598 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1 | 1 | 1 | 1 | N/A |
| Financing Cash Flow | $1 | $1 | $1 | $1 | $N/A |
| Exchange Rate Effect | 6,625 | 3,428 | -25,935 | -40,740 | -24,083 |
| Beginning Cash Position | 173,371 | 173,371 | 266,352 | 266,352 | 266,352 |
| End Cash Position | 143,744 | 158,493 | 173,371 | 179,923 | 201,628 |
| Net Cash Flow | $-29,627 | $-14,878 | $-92,981 | $-86,429 | $-64,724 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,262 | -17,853 | -59,535 | -40,193 | -37,043 |
| Capital Expenditure | -991 | -454 | -7,512 | -5,497 | -3,598 |
| Free Cash Flow | -36,253 | -18,307 | -67,047 | -45,690 | -40,641 |